News
Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed 53% in the aftermath of the readout. Altimmune’s dual GLP-1/glucagon agonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback